MicroStrategy Chairman Michael Saylor said he will deliver a three-minute pitch to Microsoft’s directors on why the firm ...
In September 2024, UCB and Biogen reported successful results from their Phase III clinical trial of the PHOENYCS GO study, which tested dapirolizumab pegol as a treatment for moderate-to-severe ...